Rhenopharma Group has acquired Konapharma AG, a Swiss contract manufacturer for the pharmaceutical industry. This strategic acquisition strengthens Rhenopharma’s global position as a provider of integrated pharmaceutical services. Konapharma now joins the group of companies that includes packaging company Allpack
Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, has announced that Kite Pharma, a Gilead Company, will evaluate its automated manufacturing platform, the Cell Shuttle. This proof-of-concept evaluation aims to generate
Veranova, a developer and manufacturer of specialist and complex APIs for the pharmaceutical and biotech sectors, has initiated a significant expansion of its antibody-drug conjugate (ADC) and highly potent compound development and manufacturing capabilities at its Devens, MA facility. This
CMC – Chemistry, Manufacturing and Controls in Drug Development Chemistry, Manufacturing, and Controls (CMC) represents one of the most critical aspects of pharmaceutical development, ensuring that every drug reaching patients meets the highest standards of quality, safety, and efficacy. From
SK bioscience has acquired a controlling stake in IDT Biologika, a German contract development and manufacturing organization (CDMO), for 339 billion won ($243.9 million). The deal, finalized through an agreement with the Klocke Group, gives SK bioscience 60% of IDT
Evotec SE’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., has been selected by the U.S. Department of Defense (DoD) to develop an accelerated monoclonal antibody (mAb) development and manufacturing solution. This initiative is part of the DoD’s Manufacturing Optimization Program
ProBio Inc., a New Jersey-based contract development and manufacturing organization (CDMO), has expanded its manufacturing capabilities with the opening of a new facility in Hopewell, New Jersey. This new site will serve as the hub for North American operations, significantly
Novo Nordisk has announced plans to invest $4.1 billion to build a second fill and finish manufacturing facility in Clayton, North Carolina. This expansion aims to increase production capacity for current and future injectable treatments for obesity and other serious
Charles River Laboratories International Inc. and the Gates Institute at the University of Colorado Anschutz Medical Campus have entered into a contract development and manufacturing organization (CDMO) agreement. This partnership will see Gates Institute leveraging Charles River’s expertise in cell
SK Inc., the holding and investment company of South Korea’s SK Group, is in the final stages of negotiations to sell a major asset of its contract drug-making unit, SK Pharmteco Co., to Novo Nordisk A/S. The asset in question
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
